Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $105.2 million.

  • Benitec Biopharma's Liabilities and Shareholders Equity rose 60144.01% to $105.2 million in Q1 2025 from the same period last year, while for Jun 2025 it was $253.1 million, marking a year-over-year increase of 11887.38%. This contributed to the annual value of $52.2 million for FY2024, which is 106957.89% up from last year.
  • According to the latest figures from Q1 2025, Benitec Biopharma's Liabilities and Shareholders Equity is $105.2 million, which was up 60144.01% from $79.1 million recorded in Q4 2024.
  • Benitec Biopharma's Liabilities and Shareholders Equity's 5-year high stood at $105.2 million during Q1 2025, with a 5-year trough of $4.5 million in Q2 2023.
  • For the 5-year period, Benitec Biopharma's Liabilities and Shareholders Equity averaged around $29.1 million, with its median value being $17.8 million (2021).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 7206.14% in 2022, then skyrocketed by 106957.89% in 2024.
  • Quarter analysis of 5 years shows Benitec Biopharma's Liabilities and Shareholders Equity stood at $14.0 million in 2021, then dropped by 15.05% to $11.9 million in 2022, then surged by 79.36% to $21.4 million in 2023, then soared by 270.29% to $79.1 million in 2024, then soared by 33.06% to $105.2 million in 2025.
  • Its Liabilities and Shareholders Equity was $105.2 million in Q1 2025, compared to $79.1 million in Q4 2024 and $68.8 million in Q3 2024.